- Home
- PLUR
PLUR
Pluri Inc.
as 04-03-2025 4:00pm EST
| Founded: | 2001 | Country: | Israel |
| Employees: | N/A | City: | HAIFA |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 8.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.91 - $6.60 | Next Earning Date: | 05-09-2025 |
| Revenue: | $678,000 | Revenue Growth: | 89.92% |
| Revenue Growth (this year): | 472.39% | Revenue Growth (next year): | 254.29% |
Latest Pluri Inc. News
PLUR Breaking Stock News: Dive into PLUR Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise
GlobeNewswire
a month ago
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
GlobeNewswire
a month ago
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
Associated Press Finance
2 months ago
Pluri: Fiscal Q2 Earnings Snapshot
GlobeNewswire
2 months ago
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
TipRanks
2 months ago
Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market
GlobeNewswire
2 months ago
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
GlobeNewswire
4 months ago
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Compare PLUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLUR Pluri Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.